Idiopathic pericarditis

Article written and reviewed by Dr Luca Moretti

Idiopathic pericarditis is pericardial inflammation for which no specific cause is identified after a clinical and instrumental assessment appropriate to the presentation and individual risk. The term does not designate a single biologic mechanism and does not mean that every possible test must have been performed. Rather, it expresses the result of a reasoned pathway in which the main relevant alternatives have been considered and insufficient evidence has emerged to attribute the disease to documented infection, neoplasia, systemic disease, metabolic abnormality, or iatrogenic injury.

Idiopathic and presumed viral forms are frequently grouped together in case series, particularly in countries with a low prevalence of tuberculosis. A preceding viral illness may represent a possible trigger but does not permit an idiopathic diagnosis to be converted into proven viral pericarditis. In persistent or recurrent forms, immune-mediated mechanisms become relevant and may continue even when the initial event is no longer identifiable. Uncertainty about the original cause therefore does not prevent characterization of inflammatory activity and selection of phenotype-based treatment.

The course ranges from a single self-limited episode to disease with recurrences and treatment dependence. Vital prognosis is generally favorable in appropriately evaluated patients, whereas pain, exercise limitation, and treatment toxicity may have a considerable impact. The diagnosis must remain open to verification over time: new systemic signs or an unexpected course may require etiologic reclassification without necessarily making the initial assessment inappropriate.

Unidentified etiology and immune mechanisms

The idiopathic category is heterogeneous because it includes both causes not sought invasively when the expected benefit would be minimal and processes that cannot be identified with available tools. In an immunocompetent person with a typical episode and rapid improvement, the absence of biopsy or pericardial molecular testing does not make the evaluation incomplete. Conversely, the same definition is less robust if used without further investigation in the presence of persistent fever, a large effusion, immunosuppression, or constitutional symptoms. The adequacy of exclusion depends on the probability and consequences of the alternatives.

A possible infectious trigger may precede the disease without being demonstrable at the time of diagnosis. The local and systemic response may continue after pathogen clearance and does not require persistent replication. This hypothesis is compatible with some courses but does not justify considering every case an occult infection or prescribing empiric antivirals. Distinguishing the initial event from the maintenance mechanism is particularly important when recurrences occur months later without evidence of new infections.

Innate immunity contributes in some patients through damage signals, myeloid recruitment, and production of proinflammatory mediators. Activation of the NLRP3 inflammasome promotes maturation of cytokines such as interleukin-1β, while other signals released by damaged cells may amplify the circuit. Experimental research and the efficacy of interleukin-1-directed therapies in selected recurrent forms support this model. However, no routine clinical test demonstrates inflammasome activation in every individual idiopathic episode.

The autoinflammatory phenotype tends to manifest as attacks accompanied by fever, elevated C-reactive protein, and sometimes serositis at other sites. Clinical and genetic analyses of referral populations show overlap with autoinflammatory diseases but do not allow automatic attribution of a monogenic syndrome to all recurrences. Age at onset, family history, periodicity of fevers, geographic origin, and extrapericardial manifestations identify cases in which genetic evaluation may provide useful information. Variants of uncertain significance require specialist interpretation and should not become stand-alone diagnoses.

Adaptive immunity may participate to varying degrees. The presence of autoantibodies or association with other immune manifestations may suggest a different phenotype, but an isolated low-titer positive result is often nonspecific. A systemic autoimmune disease must be recognized through the totality of its criteria and organ manifestations. When such a disease is demonstrated, the pericarditis is no longer properly idiopathic, even if the pericardial onset preceded the other signs by some time. Diagnostic change reflects the evolution of the available information.

Persistence factors do not necessarily coincide with the original cause. Incomplete control of inflammation, difficulty with adherence, poorly tolerated doses, drug interactions, and premature tapering may promote flares. The association between corticosteroids and recurrence observed in case series requires caution because more complex patients receive these drugs more often; this does not eliminate the need to use them for precise indications and with slow tapering. The number of attacks does not directly measure anatomic damage and does not imply an inevitable progressive accumulation of fibrosis.

Pathogenesis of pain, effusion, and pericardial dysfunction

Serosal inflammation alters the normal balance between production and reabsorption of pericardial fluid. Microvascular permeability increases, edema alters the layers, and exudation may deposit fibrin on their surfaces. The amount of visible fluid is only one component of the response: very painful pericarditis may have a minimal or absent effusion, whereas a large collection may be relatively asymptomatic if it developed slowly. Absence of effusion therefore does not equal absence of inflammation.

Pericarditic pain arises from irritation of sensitive structures and relationships with the pleura and diaphragm. Variations with breathing and position reflect these relationships, whereas radiation to the trapezius region is consistent with phrenic innervation. The friction rub is produced by movement of inflamed surfaces and may appear and disappear during the same course. Pain and friction rub, however, are not etiologically specific: they help recognize a pericardial syndrome, not prove that it is idiopathic.

Electrocardiographic changes reflect involvement of adjacent electrically active structures. Diffuse ST-segment elevation and PR-segment changes may support the diagnosis but do not occur in every patient and do not necessarily follow a complete sequence of stages. The extent or persistence of changes should be interpreted together with symptoms, troponin, and imaging. An ischemic presentation should not be excluded solely because the pain is pleuritic or because there was a previous pericardial episode.

C-reactive protein reflects the systemic inflammatory response and may be useful for monitoring the course, but it is not a direct measure of the amount of pericardial disease. It may be normal early, after treatment, or in phenotypes with predominantly local activity. Its normalization supports control when it was initially elevated without by itself proving complete remission. Late gadolinium enhancement on magnetic resonance may also persist beyond the period of greatest activity and must be correlated with edema, symptoms, and temporal course.

Tamponade results from increased intrapericardial pressure that impairs filling and reduces cardiac output. In idiopathic cases it is less common than in some specific causes, but the lower probability does not permit its signs to be ignored. Effusion size, rate of accumulation, pericardial compliance, and loading conditions all contribute to the physiology. An isolated echocardiographic finding, such as chamber collapse in a hypovolemic patient, must be interpreted together with blood pressure, perfusion, and the overall clinical picture.

Constrictive limitation may be temporarily sustained by inflammation and reduced distensibility without a definitive fibrous shell. Regression with treatment is possible in appropriate phenotypes. Persistent constriction remains uncommon in idiopathic forms and should prompt re-examination of etiology and differential diagnosis. Associated myocardial injury further modifies physiology: ventricular dysfunction, arrhythmias, or reduced output reserve should not be attributed to the pericardium alone when troponin and magnetic resonance suggest a myocardial component.

Clinical manifestations, history, and physical examination

The first episode often presents with chest pain of relatively rapid onset, worsened by deep inspiration, coughing, or the supine position and relieved by sitting and leaning forward. This description increases the plausibility of pericarditis but is not universal: less typical pain, dyspnea, or asthenia may predominate in older adults and previously treated patients. Response to an anti-inflammatory drug is compatible with the process but does not replace objective assessment or exclude concomitant disease.

Low-grade fever and general malaise may accompany the attack. High or persistent fever, especially with chills, deterioration in general condition, or focal signs of infection, instead requires caution before assigning an idiopathic cause. A preceding respiratory syndrome is common in the clinical history but should be described as a possible association. Tuberculosis contacts, immunosuppression, and travel remain relevant even when the episode otherwise appears typical because they modify the safety of an empiric pathway.

The history must reconstruct episodes and remissions. A recurrence requires a new episode after an interval of remission, whereas symptoms that never truly resolved indicate an incessant course. This distinction is not merely terminologic: it helps assess whether therapy controlled the previous attack and whether treatment was tapered in the presence of residual activity. Objectively inflammatory pain must also be separated from persistent chest symptoms of another origin, particularly when tests show no reactivation.

The search for extrapericardial signs includes arthritis, rash, ulcers, gastrointestinal symptoms, episodes of periodic fever, and other serositis. A systemic disease may become evident only after multiple attacks. Family history should cover not only the word pericarditis but also recurrent fevers and unexplained inflammatory syndromes. Neoplasia, renal failure, thoracic irradiation, procedures, and new medications are equally important because a recognizable alternative explanation makes the idiopathic classification inappropriate.

On cardiovascular examination heart rate, blood pressure, peripheral perfusion, heart sounds, friction rub, and venous pressure are assessed. The rub may be better heard with the patient leaning forward and should be sought without turning its absence into an exclusion criterion. Jugular venous distention, hypotension, disproportionate tachycardia, pulsus paradoxus, or oliguria raise suspicion of hemodynamic compromise. Pulmonary auscultation and assessment of edema help distinguish pericardial compression, ventricular dysfunction, and respiratory disease.

The impact on quality of life may be substantial even when mortality indicators remain favorable. Unpredictable recurrences, fear of exertion, sleep disturbance, and work difficulties require explicit assessment. Pain should not be dismissed when tests are normal, but neither should it automatically be interpreted as proof of inflammation requiring greater immunosuppression. Accurate assessment allows symptoms, deconditioning, and musculoskeletal or psychological components to be managed without losing surveillance of organic disease.

Diagnosis of pericarditis and idiopathic attribution

Diagnosis proceeds on two levels: demonstrating a pericardial syndrome and establishing that, in the specific context, there is no evidence of a defined cause. The first level integrates the clinical presentation, friction rub, ECG, effusion, and imaging signs of inflammation. Classic criteria required at least two among typical pain, friction rub, diffuse ST/PR changes, and new or increased effusion; contemporary documents also emphasize multimodality confirmation and inflammatory markers. The diagnostic model used should be explicit and not based on pain alone.

Echocardiography is the initial test to assess effusion, effects on filling, and ventricular function. A normal examination does not exclude pericarditis without effusion. ECG and troponin help evaluate myocardial involvement and the ischemic differential diagnosis; complete blood count, C-reactive protein, renal function, and electrolytes generally complete the initial assessment. The choice of further tests depends on the findings, avoiding interpretation of a series of normal results as automatic proof of idiopathic etiology.

Conditions supporting a clinically reasoned idiopathic attribution

• Documented pericardial syndrome with coherent clinical and objective findings.
• History and physical examination without a convincing secondary cause.
• Risk assessment and investigations proportionate to epidemiology, comorbidities, and presentation.
• No findings demonstrating a specific infection, neoplasia, or causal systemic disease.
• Reassessment plan capable of recognizing a course incompatible with the initial hypothesis.

This set describes an operational pathway, not a validated score. In low-risk patients it is not necessary to demonstrate the absence of every microorganism through invasive procedures. Systematic testing for viral antibodies tends to produce evidence of past exposure rather than causal proof. Likewise, broad autoimmune panels in the absence of relevant signs may generate misleading signals. Tests should be ordered when a reliable result would change diagnostic probability or clinical management.

Magnetic resonance imaging becomes particularly useful in uncertain cases, recurrences with few conventional signs, or when myocardial involvement is suspected. Pericardial edema and enhancement may support the presence of inflammation but do not reliably distinguish idiopathic disease, infection, and systemic disease. Late enhancement alone, especially if persistent after an episode, is not equivalent to reactivation. CT is selected when thoracic disease, masses, calcifications, or findings not adequately clarified by magnetic resonance need to be evaluated.

The differential diagnosis of chest pain remains essential even in a patient with known pericarditis. Acute coronary syndrome, pulmonary embolism, and acute aortic syndrome require urgent pathways when clinically plausible; pneumonia, pleuritis, reflux, and chest wall pain may produce overlapping symptoms. A previous idiopathic label does not protect against new disease. In particular, a change in the nature of pain, instability, hypoxemia, or new ECG findings should prompt reassessment without anchoring on the pre-existing diagnosis.

Further investigations and conditions for revising the diagnosis

Idiopathic classification requires longitudinal verification. During the first days, symptoms, treatment tolerability, inflammatory markers when useful, and any effusion are reassessed. Failure to improve after an appropriate regimen requires first checking diagnosis, adherence, dose, and interactions, but should also reopen the search for specific causes. Lack of response does not automatically mean refractory autoinflammatory disease and does not by itself justify immediate escalation to biologic therapy.

Signals for diagnostic revision include persistent fever, night sweats, weight loss, lymphadenopathy, an enlarging effusion, recurrences with new features, and development of constriction. In these settings, targeted investigations for tuberculosis, bacterial infection, neoplasia, or immune disease are appropriate. A negative test obtained very early or after treatment may have different limitations from one performed under optimal conditions. Reasoning should make these limitations explicit rather than treating all negative results as equivalent.

Autoimmune investigation is guided by organ manifestations. Urinalysis, renal function, complement, and specific autoantibodies may be relevant when the presentation suggests lupus or other conditions. Interpretation requires attention to titer, specificity, and pretest probability. If a connective tissue disease emerges, the therapeutic strategy must consider systemic involvement rather than simply adding drugs for pericardial pain. In the absence of a coherent phenotype, an isolated positive result should not turn a patient into a carrier of a defined autoimmune disease.

Autoinflammatory assessment is particularly relevant with early onset, family history, recurrent fevers, and multiple serositis. Depending on the phenotype, suspicion may involve familial Mediterranean fever, tumor necrosis factor receptor-associated syndromes, or other disorders. Specialist consultation precedes or accompanies selection of the genetic panel. The result must be correlated with penetrance and the clinical significance of the variant; response to colchicine or an interleukin-1 inhibitor alone does not identify a specific genetic syndrome.

Pericardial sampling is not required in typical low-risk recurrences. It becomes relevant when there is an indication for drainage, substantial suspicion of infection or malignancy, or a persistent collection requiring clarification that could change treatment. Cytology, cultures, and targeted analyses should be planned before the procedure. Biopsy is reserved for selected situations and may be useful during an already necessary operation; nonspecific fibrosis does not automatically close the investigation.

Before prolonged immunomodulatory therapy infectious risk, vaccinations when indicated, complete blood count, liver and renal function, and possible interactions should be reassessed. Screening should follow the drug being considered and the context, without being confused with an indiscriminate search for the cause of pericarditis. It is useful to define goals in advance: clinical remission, reduction of documented inflammation, steroid discontinuation when possible, and functional recovery. Reaching these goals allows efficacy to be judged without relying solely on momentary disappearance of pain.

Treatment of the episode and management of persistent phenotypes

In a first uncomplicated idiopathic episode, aspirin or NSAIDs at anti-inflammatory doses generally form the basis of treatment, combined with colchicine when not contraindicated. Adult regimens commonly used include aspirin 750-1,000 mg every eight hours or ibuprofen 600-800 mg every eight hours; selection depends on cardiovascular and gastrointestinal risk, renal function, concomitant therapies, and tolerability. Doses cannot be automatically transferred to children, pregnancy, or organ failure. Gastroprotection accompanies appropriate regimens, and response is reassessed before tapering.

Colchicine reduces the probability of an incessant or recurrent course when added to conventional therapy in the populations studied. Generally, 0.5 mg once daily is used below 70 kg and twice daily at 70 kg or above, with adjustments for renal or hepatic function, age, and interactions. Usual duration is at least three months for a first episode and at least six months for recurrent forms, individualized as needed. Diarrhea and gastrointestinal intolerance require assessment; in the presence of strong CYP3A4 or P-glycoprotein inhibitors, the risk of toxicity may increase substantially.

Treatment tapering begins after clinical control and, when initially abnormal, normalization of inflammatory markers, with imaging integrated in complex cases. The full duration of NSAID treatment depends on activity rather than an immutable schedule. Stopping all drugs together makes it more difficult to understand which step favored a flare. Colchicine is generally maintained longer than the anti-inflammatory drug used for the attack. Relapse during tapering requires verification of inflammation and the previous regimen, not merely automatic dose escalation.

Corticosteroids are reserved for specific indications, contraindications, or inadequate response to conventional regimens after infectious causes have been considered. When appropriate, low- to moderate-dose prednisone, often in the range of 0.2-0.5 mg/kg per day, is preferred over unnecessarily high doses. Tapering should be slow and guided by remission, with particular caution at lower doses. Osteoporosis, metabolic effects, infections, and adrenal suppression contribute to the balance of prolonged therapy; the need for repeated courses suggests specialist reassessment.

Interleukin-1 blockade with anakinra or rilonacept has a role in selected inflammatory forms, especially with corticosteroid dependence, resistance or intolerance to conventional treatments, and documented recurrences. AIRTRIP and RHAPSODY demonstrated efficacy in defined populations, not in any idiopathic chest pain. Selection requires verification of applicable indications, infectious risk, and monitoring; response does not retrospectively prove a monogenic etiology. Duration and discontinuation should be planned recognizing that control during treatment does not guarantee stable remission after withdrawal.

Further-line options include azathioprine or other specialist immunomodulatory approaches in selected cases. Evidence is less uniform than for randomized trials of colchicine and interleukin-1 inhibitors, and treatment should reflect the phenotype. Pericardiectomy is not a routine response to idiopathic recurrences; it is discussed in exceptionally refractory cases or for persistent constriction with an independent indication, in experienced centers. Residual noninflammatory pain is not by itself a reason to remove the pericardium.

Return to activities follows achievement of remission and risk assessment, avoiding intense exercise during the active phase. Symptoms, biomarkers, ECG, imaging, and any myocardial involvement guide timing. It is not appropriate to impose an identical period of inactivity on everyone or clear sport based only on disappearance of pain. A progressive return helps distinguish deconditioning from reactivation and limits disability. Myocardial involvement requires additional criteria, particularly regarding ventricular function and arrhythmias.

Prognosis, complications, and long-term surveillance

Vital prognosis is generally good in idiopathic forms without significant myocardial involvement or hemodynamic complications. This assessment presupposes adequate evaluation and should not be applied to an unstable patient simply because no cause has yet been found. Follow-up serves to verify that the course remains coherent, that the effusion regresses or remains stable, and that no evidence of systemic disease emerges. Prognosis is therefore an estimate updated over time.

Recurrence is the main complication in terms of frequency and healthcare burden. Risk depends on population, therapy, adherence, and outcome definition and cannot be expressed as a single number valid for every patient. Colchicine reduces risk but does not abolish it. Repeated attacks may alternate with long periods of wellness, and a disease lasting years may eventually enter stable remission. There is no necessary correspondence between the number of recurrences and severity of structural damage.

Tamponade remains possible, especially when the effusion increases rapidly or the presentation prompts reconsideration of a secondary cause. Increasing dyspnea, presyncope, hypotension, oliguria, and jugular venous distention require urgent reassessment. Risk is not measured by pain, and relief of pain does not guarantee that the collection has decreased. In patients with a significant effusion, the frequency of echocardiographic follow-up is adapted to clinical course, size, and effects on filling.

Persistent constriction is rare compared with specific bacterial etiologies. Its detection requires functional confirmation and investigation for alternatives or initially unrecognized causes. Transient constrictive physiology may instead accompany an inflammatory episode and regress. Persistent jugular venous distention, edema, ascites, and reduced exercise capacity should not be overlooked simply because ejection fraction is preserved. When necessary, magnetic resonance and hemodynamic study complement echocardiography to distinguish constriction, restriction, and other causes of congestion.

Treatment complications may become an important component of the course: renal and gastrointestinal injury from anti-inflammatory drugs, colchicine toxicity or interactions, and metabolic and infectious consequences of steroids. Periodic monitoring should be proportionate to the regimen used and comorbidities. New asthenia, cytopenia, muscle weakness, or organ-function abnormality requires consideration of medications as well. Reducing toxicity is part of the therapeutic goal, not a secondary issue compared with preventing pain.

Long-term surveillance integrates remission, independence, and treatment sustainability. It is useful for the patient to have clear instructions on warning signs and on the pathway for documenting a possible new attack before changing medications independently. Management of sleep disturbance, fear of exertion, and deconditioning promotes recovery. When the idiopathic diagnosis continues to explain the picture, systematic repetition of every etiologic test is unnecessary; when new elements emerge, willingness to revise it becomes a concrete measure of clinical quality.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Wang TKM et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025;86(25):2691-2719.
3. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
4. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
5. Mauro AG et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137-150.
6. Peet CJ et al. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. Journal of the American Heart Association. 2022;11(11):e024931.
7. Imazio M et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-1097.
8. Imazio M et al. A randomized trial of colchicine for acute pericarditis. New England Journal of Medicine. 2013;369(16):1522-1528.
9. Imazio M et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Annals of Internal Medicine. 2011;155(7):409-414.
10. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.
11. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.
12. Imazio M et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.
13. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
14. Brucato A et al. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY. Journal of the American Heart Association. 2022;11(20):e023252.
15. Imazio M et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739-2744.
16. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.